Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
Growing Regenerative Medicine Market Provides Opportunities for Cytori Therapeutics
For many breast cancer patients, the effects of undergoing a mastectomy go well beyond the physical.
Cytori’s Cardiac Celution: Encouraging Interim Data
In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction and chronic myocardial ischemia.
